Bio Non Currrent Assets Other from 2010 to 2024
BPTH Stock | USD 2.14 0.20 8.55% |
Non Currrent Assets Other | First Reported 2005-09-30 | Previous Quarter 114 K | Current Value 54 K | Quarterly Volatility 2.4 M |
Check Bio Path financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio main balance sheet or income statement drivers, such as Depreciation And Amortization of 179.9 K, Interest Expense of 31.2 K or Selling General Administrative of 3.9 K, as well as many exotic indicators such as Price To Sales Ratio of 9.4 K, Dividend Yield of 0.0 or PTB Ratio of 9.54. Bio financial statements analysis is a perfect complement when working with Bio Path Valuation or Volatility modules.
Bio | Non Currrent Assets Other |
Latest Bio Path's Non Currrent Assets Other Growth Pattern
Below is the plot of the Non Currrent Assets Other of Bio Path Holdings over the last few years. It is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. Bio Path's Non Currrent Assets Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bio Path's overall financial position and show how it may be relating to other accounts over time.
Non Currrent Assets Other | 10 Years Trend |
|
Non Currrent Assets Other |
Timeline |
Bio Non Currrent Assets Other Regression Statistics
Arithmetic Mean | (716,589) | |
Geometric Mean | 0.00 | |
Coefficient Of Variation | (492.47) | |
Mean Deviation | 1,691,788 | |
Median | 365.00 | |
Standard Deviation | 3,528,982 | |
Sample Variance | 12.5T | |
Range | 14.8M | |
R-Value | (0.10) | |
Mean Square Error | 13.3T | |
R-Squared | 0.01 | |
Significance | 0.71 | |
Slope | (81,564) | |
Total Sum of Squares | 174.4T |
Bio Non Currrent Assets Other History
About Bio Path Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Bio Path income statement, its balance sheet, and the statement of cash flows. Bio Path investors use historical funamental indicators, such as Bio Path's Non Currrent Assets Other, to determine how well the company is positioned to perform in the future. Although Bio Path investors may use each financial statement separately, they are all related. The changes in Bio Path's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bio Path's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Bio Path Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Bio Path. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Non Currrent Assets Other | 76 K | 79.8 K |
Currently Active Assets on Macroaxis
When determining whether Bio Path Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Path's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Path Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Path Holdings Stock:Check out the analysis of Bio Path Correlation against competitors. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Bio Stock analysis
When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Bio Path's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (33.63) | Return On Assets (1.38) | Return On Equity (4.31) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.